Bioluminescence Ventures Strengthens Senior Team with Appointment of Campbell Murray as Senior Partner
July 30 2024 - 8:30AM
Business Wire
Veteran biotech investor and entrepreneur to
drive strategic growth and portfolio development
Bioluminescence Ventures (“BLV”), a biotech venture firm
investing in next-generation medicines to address unmet medical
needs, today announced the appointment of Campbell Murray, M.D.,
MPP, MBA to the firm as a Senior Partner. Dr. Murray brings
extensive leadership, clinical and operational experience from his
years of working with high-growth companies as an investor, leader,
entrepreneur and advisor.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240730705010/en/
Campbell Murray, MD (Photo: Business
Wire)
“I am privileged and excited to welcome Campbell Murray to the
Bioluminescence Ventures team," said Founding and Managing Partner
Kouki Harasaki, Ph.D. "Campbell will work with our venture team to
identify and assess mission-driven biotechnology companies within
our focused disciplines. His background in medicine and wealth of
life science expertise, from seed to exit, will be invaluable to
our portfolio companies as they advance their therapeutic programs
from bench to bedside."
Campbell Murray, M.D. joins Bioluminescence Ventures (BLV) as a
Senior Partner, bringing over two decades of experience in venture
capital, biotech operations, and clinical medicine. Most recently,
Dr. Murray was a general partner at Agent Capital. Previously, he
spent more than 16 years with Novartis Venture Fund (NVF), where as
Managing Director he invested over $200 million across a portfolio
that yielded 6 M&A exits and 11 IPOs. His entrepreneurial
experience includes serving as President & Chief Operating
Officer of Diabetes Free and Intima Bioscience, and he has served
on the Board of Directors of 22 emerging biotechnology
companies.
A Kauffman Fellow (Class 11), he holds a Bachelor of Human
Biology and an MBChB (MD) from the University of Auckland Medical
School. He also holds an MPP from Harvard's Kennedy School of
Government and an MBA from Harvard Business School.
"I am thrilled to join Bioluminescence Ventures at such a
pivotal time for innovation in the biotech sector," said Dr.
Murray. "BLV's commitment to advancing groundbreaking therapies
aligns with my passion for fostering transformative medical
advancements. I look forward to leveraging my experience to support
the growth of pioneering companies in our portfolio and contribute
to BLV's mission of improving patients' lives through strategic
investments in cutting-edge science."
About Bioluminescence Ventures (BLV)
Bioluminescence is a leading US biotechnology venture capital
firm investing in the future of medicine. We are inspired by the
accelerating pace of biomedical innovation and its recent impact on
humanity. We are mission-driven – investing our time, energy, and
capital into translating transformative science into
next-generation medicines that will impact patients. The firm
focuses investments on four areas: Breakthrough Biology, Drug
Discovery Platforms, Genetic Medicines Platforms, and Computational
Biology Platforms. For more information, please visit
Bioluminescence.com and follow us on LinkedIn and X.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240730705010/en/
Media Contact Michelle Linn Linnden Communications
michelle@linndencom.com